Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals Inc. (IONS)
:IONS
Earnings Data
Report Date
Feb 25, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.35Last Year’s EPS
-0.66Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Ionis Pharmaceuticals demonstrated strong revenue growth and successful product launches, with significant advancements in their clinical pipeline. Despite these achievements, the company faces challenges with operating losses and patient identification for Tringolza. Overall, the positive developments outweigh the challenges.Company Guidance
Strong Revenue Growth
Ionis Pharmaceuticals reported a 17% increase in revenue year over year for the third quarter of 2025, totaling $157 million. The first nine months saw a 55% increase in revenue compared to the previous year.
Successful Launch of Tringolza
Tringolza, the treatment for familial chylomicronemia syndrome (FCS), achieved $32 million in net product sales in Q3, a nearly 70% increase from the second quarter.
Regulatory and Market Approvals
Tringolza received European approval, and Donzara was approved by the FDA for Hereditary Angioedema (HAE).
Positive Clinical Trial Results
Olazarsen showed significant reductions in triglycerides in severe hypertriglyceridemia (SHTG) patients, achieving a 72% reduction in triglycerides and an 85% reduction in acute pancreatitis events.
Advancements in Neurology
Zilgarnason showed the first-ever disease-modifying effect in Alexander disease, achieving a 33% mean benefit in gait speed.
IONS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IONS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 29, 2025 | $73.57 | $71.88 | -2.30% |
Jul 30, 2025 | $41.48 | $43.37 | +4.56% |
Apr 30, 2025 | $29.81 | $30.71 | +3.02% |
Feb 19, 2025 | $31.95 | $31.81 | -0.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ionis Pharmaceuticals Inc. (IONS) report earnings?
Ionis Pharmaceuticals Inc. (IONS) is schdueled to report earning on Feb 25, 2026, Before Open (Confirmed).
What is Ionis Pharmaceuticals Inc. (IONS) earnings time?
Ionis Pharmaceuticals Inc. (IONS) earnings time is at Feb 25, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IONS EPS forecast?
IONS EPS forecast for the fiscal quarter 2025 (Q4) is -1.35.